iDDS probes for cancer drivers and drug-resistant mutations
Chronic myelogenous leukemia (ABL kinase drug-resistance mutations)
Our CML assay panel comprises 13 different iDDS probes for the most common secondary mutations in ABL kinase that confer drug resistance in patients with CML.
Colorectal cancer driver mutations (APC, BRAF, CTNNB1, and KRAS)
GeneTAG has developed iDDS probe assays against a panel of key driver mutations associated with colorectal cancer.
Gliomas (IDH1 & IDH2 driver mutations)
We offer iDDS probes against common driver mutations in IDH1 (R132C, R132H) and IDH2 (R172K, R172M), which have been implicated in gliomas.
Lung cancer (EGFR - driver & drug-resistance mutations)
We offer iDDS probe assays against common EGFR driver mutations (L858R and exon 19 deletions), the T790M drug-resistance mutation, and 16 other resistance mutations.